Progesterone Receptor Negative clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Orange, California and other locations